Approval of tissue-agnostic combination therapy, may require that regulatory bodies recognize that each drug within a combination therapy may not require prior tissue-agnostic approval as a monotherapy to eventually prove more effective in combination. htt
681 followers
1,654 followers
RT @gulleyj1: @NCICancerBio 4/4 Our paper discusses the FDA approval of anti-PD1 therapy for patients with biomarker defined disease (lots…
1,132 followers
RT @gulleyj1: @NCICancerBio 4/4 Our paper discusses the FDA approval of anti-PD1 therapy for patients with biomarker defined disease (lots…
7,570 followers
@NCICancerBio 4/4 Our paper discusses the FDA approval of anti-PD1 therapy for patients with biomarker defined disease (lots of mutations) regardless of cancer type. https://t.co/Syl4ZTJH5q #CIM22 #CIMChat22